Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1375-1380, 2003; 10.1373/49.8.1375
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (24)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huck, J. H.J.
Right arrow Articles by van der Knaap, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huck, J. H.J.
Right arrow Articles by van der Knaap, M. S.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2003;49:1375-1380.)
© 2003 American Association for Clinical Chemistry, Inc.

Endocrinology and Metabolism

Profiling of Pentose Phosphate Pathway Intermediates in Blood Spots by Tandem Mass Spectrometry: Application to Transaldolase Deficiency

Jojanneke H.J. Huck1,2,1, Eduard A. Struys2,1, Nanda M. Verhoeven2,a, Cornelis Jakobs2 and Marjo S. van der Knaap1

1 Department of Pediatrics and
2 Metabolic Unit of the Department of Clinical Chemistry, VU University Medical Centre, 1081 HV Amsterdam, The Netherlands.

aAddress correspondence to this author at: Metabolic Unit, Department of Clinical Chemistry, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Fax 31-20-4440305; e-mail N.Verhoeven{at}vumc.nl.

Background: Recently, several patients with abnormal polyol profiles in body fluids have been reported, but the origins of these polyols are unknown. We hypothesized that they are derived from sugar phosphate intermediates of the pentose phosphate pathway (PPP), and we developed a semiquantitative method for profiling of pentose phosphate pathway intermediates.

Methods: Sugar phosphates in blood spots were simultaneously analyzed by liquid chromatography–tandem mass spectrometry using an ion-pair-loaded C18 HPLC column. The tandem mass spectrometer was operated in the multiple-reaction monitoring mode. Enzymatically prepared D-[13C6]glucose 6-phosphate was used as internal standard. The method was used to study sugar phosphates abnormalities in a patient affected with a deficiency of transaldolase (TALDO1; EC 2.2.1.2).

Results: In control blood spots, dihydroxyacetone phosphate, pentulose 5-phosphates, pentose 5-phosphates, hexose 6-phosphates, and sedoheptulose 7-phosphate were detected. Detection limits ranged from ~100 to ~500 nmol/L. Glyceraldehyde 3-phosphate and erythrose 4-phosphate were undetectable. Intra- and interassay imprecision (CVs) were 10–17% and 12–21%, respectively. In blood from the TALDO1-deficient patient, sedoheptulose 7-phosphate was increased.

Conclusions: The new method allows investigation of patients in whom a defect in the PPP is suspected. Measurements of sugar phosphate intermediates of the PPP may provide new insights into metabolic defects underlying the accumulating polyols.




The following articles in journals at HighWire Press have cited this article:


Home page
 Cardiovasc ResHome page
C.J Zuurbier, O Eerbeek, P.T Goedhart, E.A Struys, N.M Verhoeven, C Jakobs, and C Ince
Inhibition of the pentose phosphate pathway decreases ischemia-reperfusion-induced creatine kinase release in the heart
Cardiovasc Res, April 1, 2004; 62(1): 145 - 153.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.